Evidence map›Paper›PMID 32349420›Full record

ReviewMolecules (Basel, Switzerland)2020

Isofraxidin: Synthesis, Biosynthesis, Isolation, Pharmacokinetic and Pharmacological Properties.

Mohammad Bagher Majnooni, Sajad Fakhri, Yalda Shokoohinia, Mahdi Mojarrab, Sara Kazemi-Afrakoti, Mohammad Hosein Farzaei

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A Substrate-Dependent Bifunctional Dioxygenase fromMolecules (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Article
  7. Frontiers in immunology · 2026
    Review
  8. Molecules (Basel, Switzerland) · 2025
    Review
  9. Article
  10. Frontiers in pharmacology · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. The genusFrontiers in pharmacology · 2022
    Review
  17. Review
  18. Frontiers in cellular and infection microbiology · 2022
    Article
  19. Genome and Metabolome MS-Based Mining of a Marine Strain ofJournal of fungi (Basel, Switzerland) · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Mohammad Bagher MajnooniStudent Research Committee, Kermanshah University of Medical Sciences, Kermanshah 6714415153, Iran.
Sajad FakhriPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.ORCID 0000-0001-8265-8284
Yalda ShokoohiniaPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.ORCID 0000-0003-3714-0835
Mahdi MojarrabPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.
Sara Kazemi-AfrakotiStudent Research Committee, Kermanshah University of Medical Sciences, Kermanshah 6714415153, Iran.
Mohammad Hosein FarzaeiPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.ORCID 0000-0001-7081-6521
Kermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isofraxidin (7-hydroxy-6, 8-dimethoxy coumarin) (IF) is a hydroxy coumarin with several biological and pharmacological activities. The plant kingdom is of the most prominent sources of IF, which, among them,

Indexed as

AnimalsAnti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsCardiotonic AgentsCoumarinsEleutherococcusFraxinusHumansMatrix MetalloproteinasesNeuroprotective AgentsNF-kappa BSolventsTumor Necrosis Factor-alphaAnti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsCardiotonic AgentscoumarinCoumarinsisofraxidinMatrix MetalloproteinasesNeuroprotective AgentsNF-kappa BSolventsTumor Necrosis Factor-alphabiological activitiesbiosynthesishydroxy coumarinisofraxidinpharmacokineticspharmacology

Identifiers

PMID32349420
PMCPMC7248759
OpenAlexW3017502398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.